NattoPharma ASA said its second-quarter normalized net income was a loss of 13 Norwegian øre per share, compared with the S&P Capital IQ consensus estimate of a loss of 17 øre per share.

The per-share loss decreased 56.2% year over year from 30 øre.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of 2.2 million kroner, compared with a loss of 4.6 million kroner in the prior-year period.

The normalized profit margin climbed to negative 16.6% from negative 59.9% in the year-earlier period.

Total revenue increased 72.6% year over year to 13.3 million kroner from 7.7 million kroner, and total operating expenses increased 7.0% year over year to 16.7 million kroner from 15.6 million kroner.

Reported net income totaled a loss of 3.4 million kroner, or a loss of 20 øre per share, compared to a loss of 7.2 million kroner, or a loss of 47 øre per share, in the prior-year period.

As of Aug. 17, US$1 was equivalent to 8.23 Norwegian kroner.